Preoperative Nebulized Dexmedetomidine on Hemodynamic Changes in Laparoscopic Bariatric Surgery.

Launched by TANTA UNIVERSITY · Aug 23, 2023

Keywords

ClinConnect Summary

This clinical trial is investigating the use of a medication called dexmedetomidine, delivered through a nebulizer, to see if it helps reduce changes in blood pressure and heart rate during laparoscopic bariatric surgery in morbidly obese patients. The goal is to determine if using this medication before surgery can make the process smoother and safer for patients when they undergo procedures that require general anesthesia.

To participate, individuals must be between 18 and 50 years old, have a body mass index (BMI) between 40 and 50, and be scheduled for elective laparoscopic bariatric surgery. This study will include both men and women, totaling around 90 participants. However, those with certain health issues, such as severe heart or lung problems, and individuals who are currently taking specific medications or have psychiatric conditions, will not be eligible. Patients who join the study can expect to receive the nebulized medication before their surgery and will be monitored closely to assess how it affects their body's response during the procedure.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • This study will include 90 adult morbidly obese patients of both sex with BMI (40-50), (ASA) III physical status, aged between 18 -50 years scheduled for elective laparoscopic bariatric surgery under general anesthesia.
• Exclusion Criteria:
• • 1. Patient's refusal.
• • 2. Decompensated hepatic or renal or cardiac disease.
• • 3. Expected difficult airway management.
• • 4. Uncontrolled hypertension.
• • 5. Psychiatric disease.
• • 6. Sever pulmonary disorders.
• • 7. Patients on opioid, alcohol, beta-blockers or allergy to any of the study drugs.